These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 10801168)

  • 21. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
    Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
    JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.
    Vitner EB; Farfel-Becker T; Eilam R; Biton I; Futerman AH
    Brain; 2012 Jun; 135(Pt 6):1724-35. PubMed ID: 22566609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
    Schiffmann R; Heyes MP; Aerts JM; Dambrosia JM; Patterson MC; DeGraba T; Parker CC; Zirzow GC; Oliver K; Tedeschi G; Brady RO; Barton NW
    Ann Neurol; 1997 Oct; 42(4):613-21. PubMed ID: 9382473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
    Platt FM; Neises GR; Dwek RA; Butters TD
    J Biol Chem; 1994 Mar; 269(11):8362-5. PubMed ID: 8132559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropathic Gaucher's disease with normal 4-methylumbelliferyl-beta-glucosidase activity in the liver.
    Owada M; Sakiyama T; Kitagawa T
    Pediatr Res; 1977 May; 11(5):641-6. PubMed ID: 870871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks of Gaucher's treatment.
    Barranger JA
    Lancet; 2000 Oct; 356(9238):1353-4. PubMed ID: 11073045
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
    J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.
    Cox TM; Aerts JM; Andria G; Beck M; Belmatoug N; Bembi B; Chertkoff R; Vom Dahl S; Elstein D; Erikson A; Giralt M; Heitner R; Hollak C; Hrebicek M; Lewis S; Mehta A; Pastores GM; Rolfs A; Miranda MC; Zimran A;
    J Inherit Metab Dis; 2003; 26(6):513-26. PubMed ID: 14605497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzymic differentiation of neurologic and nonneurologic forms of Gaucher's disease.
    Glew RH; Daniels LB; Clark LS; Hoyer SW
    J Neuropathol Exp Neurol; 1982 Nov; 41(6):630-41. PubMed ID: 6813430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taliglucerase alfa for the treatment of Gaucher's disease.
    Haddley K
    Drugs Today (Barc); 2012 Aug; 48(8):525-32. PubMed ID: 22916340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gaucher's disease: rare presentation of a rare disease.
    Shrestha B; Devgan A; Sharma M
    J Child Neurol; 2013 Oct; 28(10):1296-8. PubMed ID: 22914376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gaucher disease: diagnosis and treatment].
    Fumić K; Stavljenić-Rukavina A; Mrsić M; Potocki K
    Acta Med Croatica; 2004; 58(5):353-8. PubMed ID: 15756799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.
    Damiano AM; Pastores GM; Ware JE
    Qual Life Res; 1998 Jul; 7(5):373-86. PubMed ID: 9691718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substrate reduction therapy.
    Platt FM; Jeyakumar M
    Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gaucher's disease.
    Patel AL; Shaikh WA; Khobragade AK; Soni HG; Joshi AS; Sahasrabudhe GS; Chole PV
    J Assoc Physicians India; 2009 May; 57():410-1. PubMed ID: 19634291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE; Aerts JM; Goudsmit R; Phoa SS; Ek M; van Weely S; von dem Borne AE; van Oers MH
    Lancet; 1995 Jun; 345(8963):1474-8. PubMed ID: 7769902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.
    Altarescu G; Hill S; Wiggs E; Jeffries N; Kreps C; Parker CC; Brady RO; Barton NW; Schiffmann R
    J Pediatr; 2001 Apr; 138(4):539-47. PubMed ID: 11295718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease.
    Lonser RR; Walbridge S; Murray GJ; Aizenberg MR; Vortmeyer AO; Aerts JM; Brady RO; Oldfield EH
    Ann Neurol; 2005 Apr; 57(4):542-8. PubMed ID: 15786474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Enzyme therapy in children with severe forms of Gaucher's disease].
    Zeman J; Hrebícek M; Vepreková L; Kytnarová J; Houstková H; Malinová V; Hodanová K; Poupĕtová H; Ledvinová J; Hoza J
    Cas Lek Cesk; 1997 Feb; 136(3):95-7. PubMed ID: 9221177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.